Canis ISSN: 2398-2942

Oxymorphone

Synonym(s): oxy

Contributor(s): John Dodam, Sheilah Robertson

Introduction

Name

  • DuPont Merck Pharma. Manati, Puerto Rico, Endo Pharmaceuticals Inc., Chadds Ford PA.

Class of drug

  • Schedule II opioid (narcotic); controlled substance.

Description

Chemical name

  • Oxymorphone hydrochloride; 7,8-dihydro-14-hydroxymorphinone hydrochloride.

Molecular weight

  • 337.80.

Physical properties

  • White, odorless powder, soluble in water.

Storage requirements

  • Store at 15-30 degrees C.
  • Protect from light.

Uses

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Indications

  • To provide pain relief.
  • Can be used pre-emptively for elective surgical procedures.
  • Can be used to relieve pain from trauma Trauma: overview.
  • Has also been used to provide longer-term pain relief, for example that caused by osteosarcoma Osteosarcoma.

Administration

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Pharmocokinetics

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Precautions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Interactions

with other drugs

  • Can cause profound sedation when combined with acepromazine Acepromazine maleate , alpha2-agonists (xylazine Xylazine , medetomidine link Medetomidine ) and benzodiazepines.
  • Oxymoprhone may reduce the induction dose of injectable anesthetic agents and lower the dose of inhalant agents required for maintenance of anesthesia.

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading

Publications

Refereed papers

  • Smith L J, Yu J K, Bjorling D E, Waller K (2001)Effects of hydromorphone or oxymorphone, with or without acepromazine, on preanesthetic sedation, physiologic values and histamine release in dogs.JAVMA218(7),1101-5.
  • Torske K E, Dyson D H, Conlon P D (1999)Cardiovascular effects of epidurally administered oxymorphone and an oxymorphone-bupivacaine combination in halothane anesthetised dogs.Am J Vet Res60(2),194-200.
  • Kyles A E, Hardie E M, Hansen B D, Papich M G (1998)Comparison of transdermal fentanyl and intramuscular oxymorphone on post-operative behaviour after ovariohysterectomy in dogs.Res Vet Sci65(3), 245-51.

Other sources of information

  • Pascoe P J (2000)Opioid Analgesics.In:Management of Pain. Vet Clin North Am Small An Pract30(4), 757-772.

ADDED